{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:38:20Z","timestamp":1792759100055,"version":"4.5.0"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Systemic Lupus Erythematosus (SLE) and lupus nephritis (LN) carry substantial cardiorenal risks. Conventional immunosuppressive therapies primarily target inflammation but leave a burden of residual renal and metabolic damage. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) provide clear cardiorenal protection in general populations, but data specific to SLE remains limited. This systematic review and meta-analysis evaluated the efficacy and safety of SGLT2i in patients with SLE and LN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Comprehensive searches across five electronic databases (PubMed, Cochrane CENTRAL, Web of Science, Embase, and Scopus) were conducted up to April 2026 to identify randomized controlled trials (RCTs) and observational studies assessing SGLT2i in adult SLE\/LN patients. Random-effects meta-analyses were performed to synthesize cardiorenal and safety outcomes using R Software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six studies published between 2024 and 2025 were included. Pooled data demonstrated that SGLT2i use was associated with a significant improvement in estimated glomerular filtration rate (eGFR) compared to controls (MD: 4.02; 95% CI: 1.39\u20136.65; I\n                      <jats:sup>2<\/jats:sup>\n                      = 60.1%). SGLT2i significantly reduced the risks of progression to end-stage kidney disease (RR: 0.37; 95% CI: 0.25\u20130.56; I\n                      <jats:sup>2<\/jats:sup>\n                      = 11.0%), heart failure development (RR: 0.65; 95% CI: 0.56\u20130.75; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0.0%), incident lupus nephritis (RR: 0.58; 95% CI: 0.44\u20130.76; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0.0%), and re-hospitalizations (RR: 0.67; 95% CI: 0.57\u20130.79; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0.0%). Furthermore, a significant reduction in all-cause mortality was observed (RR: 0.55; 95% CI: 0.36\u20130.86; I\n                      <jats:sup>2<\/jats:sup>\n                      = 76.2%). SGLT2i treatment demonstrated an acceptable safety profile across the included cohorts. The certainty of evidence for these findings was rated as low to very low, and results remain vulnerable to residual confounding from variables such as disease activity, corticosteroid burden, and immunosuppressive regimen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Preliminary exploratory evidence suggests potential associations between SGLT2 inhibitors and cardiorenal outcomes in lupus nephritis. Given the low certainty of evidence and vulnerability to residual confounding from disease-specific variables, these hypothesis-generating findings require confirmation in well-designed randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09612033261500790","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:08:48Z","timestamp":1792494528000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium-glucose cotransporter 2 inhibitors in patients with systemic lupus erythematosus and lupus nephritis: A systematic review and meta-analysis"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6252-6708","authenticated-orcid":false,"given":"Ricardo F. O","family":"Suruagy-Motta","sequence":"first","affiliation":[{"name":"Department of Medicine, Cesmac University Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Macedo de Gusm\u00e3o","family":"Canuto","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cesmac University Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Marcovig Veiga","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cesmac University Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Cala\u00e7a de P\u00e1dua","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cesmac University Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caio Felizardo Souza Cat\u00e3o","family":"Nogueira","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cesmac University Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Morena Rocha","family":"Firmino","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cesmac University Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Augusto","family":"Souza-Carvalho","sequence":"additional","affiliation":[{"name":"Department of Medicine, Federal University of Alagoas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Martinez Institute of Mental Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Falc\u00e3o Pedrosa","family":"Costa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cesmac University Center"},{"name":"Department of Medicine, Federal University of Alagoas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria de Lourdes Castro de Oliveira","family":"Figueroa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cesmac University Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05780616"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad069"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-025-02351-0"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.43037"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152746"},{"issue":"5","key":"e_1_3_4_9_2","first-page":"1783","article-title":"Clinical experience with sodium-glucose transport 2 (SGLT2) inhibitors in patients with systemic lupus erythematosus","volume":"58","author":"Tayer-Shifman OE","unstructured":"Tayer-Shifman OE, Kenis I, Benchetrit S, et al. Clinical experience with sodium-glucose transport 2 (SGLT2) inhibitors in patients with systemic lupus erythematosus. Int Urol Nephrol. 2026. May; 58(5): 1783\u20131791.","journal-title":"Int Urol Nephrol. 2026"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2025.109178"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112379"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf257"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.16578"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2025.109149"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjo.2025.100245"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224242"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119756194"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"issue":"3","key":"e_1_3_4_22_2","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer W","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Soft [Internet] 2010; 36(3): 1. https:\/\/doi.org\/10.18637\/jss.v036.i03","journal-title":"J Stat Soft [Internet]"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_3_4_26_2","first-page":"1117","article-title":"Voclosporin versus placebo for lupus nephritis","volume":"384","author":"Rovin BH","year":"2021","unstructured":"Rovin BH, Teng YKO, Ginzler EM, et al. Voclosporin versus placebo for lupus nephritis. N Engl J Med 2021; 384: 1117\u20131128.","journal-title":"N Engl J Med"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033261500790","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09612033261500790","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033261500790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:47:36Z","timestamp":1792756056000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09612033261500790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":25,"alternative-id":["10.1177\/09612033261500790"],"URL":"https:\/\/doi.org\/10.1177\/09612033261500790","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"article-number":"09612033261500790"}}